EASD 2025 15 - 19 September 2025

Impact of semaglutide on liver-related responses in people with metabolic dysfunction-associated steatohepatitis (MASH) with/without type 2 diabetes (T2D): Post hoc analysis of the ESSENCE trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress short oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Are you a healthcare professional?